These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16945413)

  • 21. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Mangiacavalli S; Varettoni M; Zappasodi P; Pica G; Lazzarino M; Corso A
    Leuk Res; 2009 Apr; 33(4):577-8. PubMed ID: 18842298
    [No Abstract]   [Full Text] [Related]  

  • 22. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
    Hrusovsky I; Emmerich B; von Rohr A; Voegeli J; Taverna C; Olie RA; Pliskat H; Frohn C; Hess G
    Oncology; 2010; 79(3-4):247-54. PubMed ID: 21372599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib (velcade) for multiple myeloma.
    Med Lett Drugs Ther; 2003 Jul; 45(1161):57-8. PubMed ID: 12865865
    [No Abstract]   [Full Text] [Related]  

  • 24. [Bortezomib in second-line therapy].
    Musch A
    Med Monatsschr Pharm; 2005 Sep; 28(9):332-3. PubMed ID: 16163891
    [No Abstract]   [Full Text] [Related]  

  • 25. Expanding role of bortezomib in multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J
    Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical management of myeloma--state of the art.
    Harousseau JL
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Captivating bortezomib: an active but still mysterious drug.
    Di Raimondo F; Conticello C
    Leuk Res; 2010 Apr; 34(4):411-2. PubMed ID: 19819547
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
    Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
    Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 30. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
    Richardson PG; Mitsiades C; Ghobrial I; Anderson K
    Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous myeloma and bortezomib.
    Gozzetti A; Defina M; Bocchia M
    Ann Hematol; 2009 Oct; 88(10):1045. PubMed ID: 19597817
    [No Abstract]   [Full Text] [Related]  

  • 32. New agents and approaches in the treatment of multiple myeloma.
    Anderson KC
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):151-2. PubMed ID: 16224394
    [No Abstract]   [Full Text] [Related]  

  • 33. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
    Pitini V; Arrigo C; Altavilla G; Naro C
    Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
    [No Abstract]   [Full Text] [Related]  

  • 35. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of new drugs for the treatment of patients with multiple myeloma.
    Kenealy M; Prince HM
    Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bortezomib].
    Simons S; Scheulen ME; Jaehde U
    Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
    del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
    South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
    Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
    Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.